Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Lymphedema, Breast Cancer, Lymphedema
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

Lymphedema is a chronic, progressive, and debilitating condition that occurs with disruption or obstruction of the lymphatic system, which commonly occurs a result of breast cancer therapy. The purpose of this study is to determine if the use of a low risk lymphatic reconstruction procedure at the time of axillary lymph node dissection will reduce the risk of developing lymphedema. Additionally, to determine if this procedure improves objective outcomes of lymphedema and patient quality of life

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Procedure: axillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA) — lymphatic reconstruction where the cut lymphatic vessels are reconstructed by anastamosing to the veins
  • Procedure: Axillary lymphadenetomy alone — oncologic axillary lymphadenectomy
  • Procedure: axillary lymphadenectomy with soft tissue reinforcement — axillary lymphadenectomy with soft tissue reinforcement(STR)

Primary Outcomes

  • Lymphatic flow pattern of whole limb (2 yr)
  • Limb Volume (2 yr)
  • Skin thickness measurements (2 yr)
  • Bioiimpedance spectroscopy (2 yr)
  • Quality of Life- Limb-Lymphedema-Specific Quality of Life (LYMQOL) (2 yr)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-09-10
Completion: 2030-06-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Stanford University
Principal Investigators:
  • Dung Nguyen, MD, PharmD (PRINCIPAL_INVESTIGATOR) - Stanford University
Contact Information
Study Contact:
Dung Nguyen, MD, PharmD
6504929239
nguyendh@stanford.edu
Dung Nguyen, PharmD
650-498-6004
nguyendh@stanford.edu
Stanford Cancer Institute
Irene Wapnir, MD
Stanford Cancer Institute
Interventions
  • Procedure: axillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA) — lymphatic reconstruction where the cut lymphatic vessels are reconstructed by anastamosing to the veins
  • Procedure: Axillary lymphadenetomy alone — oncologic axillary lymphadenectomy
  • Procedure: axillary lymphadenectomy with soft tissue reinforcement — axillary lymphadenectomy with soft tissue reinforcement(STR)
Study Locations (1 sites)
Stanford Cancer Institute, San Francisco, California 94305 United States
Eligibility Criteria
Inclusion Criteria: * Ages 18 to 75 years (inclusive) * Patients undergoing unilateral or bilateral breast cancer related axillary lymphadenectomy * Free of distant metastasis in preoperative screening * Histology results of axillary lymph nodes could be either Negative or Positive * Patients who undergo preoperative chemotherapy can be included * Willingness and ability to provide written informed consent * Willingness and ability to comply with all study procedures Exclusion Criteria: * Primary lymphedema of the affected upper limb * Secondary lymphedema of the affected limb prior to the lymphadenectomy * Radiotherapy at the axilla before the study / surgery * Allergic reaction to porcine collagen or ICG * Receiving radiation therapy to the involved nodal basin in a period less than 4 weeks after the surgery * Concurrent participation in a clinical trial of any other investigational drug or therapy, regardless of indication, within 1 month before screening * Other medical condition that could lead to limb edema, such as (but not limited to primary lymphedema or acute venous thrombosis * Other medical condition that could result in symptoms overlapping those of lymphedema in the affected limb (e.g., pain, swelling, decreased range of motion) * Either of the following, at the time of baseline evaluation: ipsilateral:contralateral limb volume ratio\>1.1 or R0 bioimpedance ratio \> 1.106 when the nondominant limb is at risk, and 1.134 when the dominant limb is at risk. * Life expectancy \< 2 years for any reason * Pregnancy or nursing * Substance abuse (such as alcohol or drug abuse) within 6 months prior to screening * Severe psychiatric disease * Significant or chronic renal insufficiency (defined as serum creatinine \> 2.5 mg/dL or an estimated glomerular filtration rate \[eGFR\] \< 30 mL/min at screening) or requires dialytic support * Hepatic dysfunction, defined as alanine transaminase (ALT) or aspartate transaminase (AST) levels \> 3 × upper limit of the normal range (ULN) and/or bilirubin level \> 2 × ULN at screening * Absolute neutrophil count \< 1500 mm3 at screening * Hemoglobin concentration \< 9 g/dL at screening * Any reason (in addition to those listed above) that, in the opinion of the investigator, precludes full participation in the study
Conditions HR Positive HER2 Negative Advanced Breas...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

To explore the efficacy and safety of Chidamide combined with endocrine for maintenance therapy after first-line chemotherapy for HR+/HER2- breast cancer

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Chidamide — Chidamide+ exemestane/Fulvestrant/Letrozole/Anastrozole/Tamoxifen

Primary Outcomes

  • Progression-free survival (2 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-05-16
Completion: 2026-10-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital
Principal Investigators:
  • Li Zhang (PRINCIPAL_INVESTIGATOR) - Tianjin Cancer Hospital
Contact Information
Study Contact:
Li Zhang
13920003358
doctor3399@163.com
Li Zhang
13920003358
doctor3399@163.com
天津市肿瘤医院
Interventions
  • Drug: Chidamide — Chidamide+ exemestane/Fulvestrant/Letrozole/Anastrozole/Tamoxifen
Study Locations (1 sites)
天津市肿瘤医院, Tianjin, China
Eligibility Criteria
Inclusion Criteria: 1. Postmenopausal/premenopausal women aged ≥18 years and ≤70 years; 2. HR + / HER2 breast cancer confirmed by histology (note: her2-negative is defined as: (1) IHC1 + / IHC0; ②IHC2+ : FISH-); 3. Confirmed by the histology of locally advanced breast cancer (local treatment) to radical or recurrent metastatic breast cancer; 4. In the late stage of untreated or experienced a CDK4/6 with endocrine therapy of patients; 5. Researchers think that for selecting patients with chemotherapy (step 2022 guidelines recommend for internal transfer, always endocrine therapy resistance or preferred to rescue patients with endocrine therapy best choice of chemotherapy); 6. One line finish cycle disease after chemotherapy (4 to 8 cycles) to alleviate or stable, quasi follow-up maintenance treatment: a. late stage A gleam of unused CDK4/6 inhibitors + endocrine group subjects into the queue for A; b. Used in the late phase line CDK4/6 inhibitors queue B + endocrine subjects into groups; 7. Into the former group at least one measurable lesions (RECIST v1.1 standard); 8.ECOG score 0 to 2 points; 9.Always all the acute toxic reaction caused by antineoplastic therapy in screening before easing to 0 and 1 level (according to the NCI CTCAE 5.0 judgment; Hair loss, other than toxicity that the investigator believes does not pose a safety risk to the subject); 10. Functions: bone marrow neutrophils absolute acuity 1.5 x 109 / L, platelet acuity 100 x 109 / L, 90 g/L or higher hemoglobin; 11. Liver and kidney function: TBIL acuities were 1.5 x ULN; ALT and AST≤2.5 x ULN; In case of liver metastasis, ALT and AST≤ 5×ULN; BUN and Cr≤1.5×ULN and creatinine clearance ≥50 ml/min; 12.Voluntary participation in the clinical trials, signed written informed consent. Exclusion Criteria: 1. Factors that significantly affect oral drug absorption, such as inability to swallow, chronic diarrhea, and intestinal obstruction; 2. Always received HDACi anti-tumor treatment; 3. This scheme known drug components have allergy history; 4. Always with other malignant tumours within five years, not including has cured thyroid papillary carcinoma, cervical carcinoma in situ, basal cell carcinoma or skin squamous cell carcinoma of the skin; 5. Within 4 weeks before into the group participated in other clinical trials; 6. A history of immune deficiency, including test positive for HIV, or has other acquired, congenital immunodeficiency disease, or has a history of organ transplantation; 7. Unable to control the important cardiovascular disease: a history of clinical significance of long QT, stage or screen between QTc \> 450 ms; Severe cardiovascular injury (greater than a New York Heart Association (NYHA) Class II history of congestive heart failure), unstable angina or myocardial infarction within the last 6 months, or severe arrhythmia; 8. Pregnancy and lactation women patients or in infertile women baseline pregnancy test positive; Or participants of childbearing age who were unwilling to use effective contraception during the study period and for at least 8 weeks after the last dosing; 9. According to the researcher's judgment, there is serious to endanger the safety of patients, the patients completed studies or associated with disease (such as severe hypertension, diabetes, thyroid disease, active infection, etc.); 10. Always have a clear history of neurological or psychiatric disorders, including epilepsy or dementia, etc.; 11. Reference: subjects had active hepatitis (hepatitis b positive HBsAg and HBV DNA of 500 IU/ml or more; Hepatitis C reference: HCV antibody positive and HCV virus copy number \> upper limit of normal); 12. The researchers determine doesn't fit to the researchers.
Conditions HNSCC, ESCC, Esophageal Adenocarcinoma, ...
Phase PHASE1
Enrollment 150
Locations 18 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: NRM-823 — NRM-823 is a bispecific T-Cell Engager

Primary Outcomes

  • Incidence of treatment-emergent adverse events (TEAE) (From enrollment until 30 days post the last dose received by a participant)
  • Incidence of dose-limiting toxicities (DLTs) (From enrollment until 30 days post the last dose received by a participant)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-10-30
Completion: 2028-10-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Normunity AccelCo, Inc.
Principal Investigators:
  • Viviana Bozon, MD (STUDY_DIRECTOR) - Normunity AccelCo, Inc.
Contact Information
Study Contact:
Judy Schnyder, MBA
215-593-7119
judy.schnyder@normunity.com
Interventions
  • Drug: NRM-823 — NRM-823 is a bispecific T-Cell Engager
Study Locations (18 sites)
Normunity Investigational Site, Denver, Colorado 80220 United States
Normunity Investigational Site, New Haven, Connecticut 06519 United States
Normunity Investigational Site, Washington D.C., District of Columbia 20007 United States
Normunity Investigational Site, Boston, Massachusetts 02114 United States
Normunity Investigational Site, Boston, Massachusetts 02215 United States
Normunity Investigational Site, Minneapolis, Minnesota 55425 United States
Normunity Investigational Site, St Louis, Missouri 63108 United States
Normunity Investigational Site, Hackensack, New Jersey 07601 United States
Normunity Investigational Site, Maumee, Ohio 43537 United States
Normunity Investigational Site, Oklahoma City, Oklahoma 73104 United States
Eligibility Criteria
Inclusion Criteria: * Have histologically- or cytologically-diagnosed NSCLC (squamous or adenocarcinoma), TNBC, HNSCC, ESCC, esophageal adenocarcinoma, gastric/GEJ adenocarcinoma, cervical, endometrial, or ovarian cancer which is advanced or metastatic. * Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Adequate liver, renal, pulmonary, and cardiac function. * Adequate hematologic function. Exclusion Criteria: * Has received cytotoxic chemotherapy, biologic anticancer agents, checkpoint inhibitors, or radiation therapy (excluding bone-only radiation therapy) ≤3 weeks or 5 half-lives (whichever is shorter) prior to the first dose of NRM-823 * History of Grade 2 pneumonitis requiring steroids or any Grade 3 or 4 pneumonitis from any prior therapy. * Has received an investigational therapy \<4 weeks or 5 half-lives prior to the first dose of NRM823, whichever is shorter prior to the first dose of NRM-823. * With the exception of alopecia and Grade ≤2 neuropathy, any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study drug.
Conditions Breast Cancer
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to test an approach to promote well-being in Black American women diagnosed with breast cancer. The main questions it aims to answer are: * Can the Project SOAR (Speaking Our African American Realities) Awakenings online intervention improve depressive symptoms in Black American women diagnosed with breast cancer? * Can the Project SOAR (Speaking Our African American Realities) Awakenings intervention improve fatigue in Black American women diagnosed with breast cancer? * Can the Project SOAR (Speaking Our African American Realities) Awakenings intervention improve well-being in Black American women diagnosed with breast cancer? Researchers will compare the Awakenings online intervention to a comparison condition, to see if women in the Awakenings group improve on depressive symptoms, fatigue, and well-being more than women in the comparison group. Women in the comparison condition will receive materials by mail to use on their own. Participants will: * be randomized (selected by chance) to take part in four Project SOAR Gatherings, which are small group, 90-minute to two-hour online discussions with other Black American women diagnosed with breast cancer and are designed to promote well-being OR to a comparison group. Rev. Dr.(Hon) Tammie Denyse, a 20-year breast cancer survivor and patient advocate, will lead the Gatherings, along with other experts. * devote about eight hours for women in the Project SOAR Gatherings discussions and two hours for women in the comparison group. * complete online questionnaires at the beginning of the study and one month and three months later. * receive a box of resources (e.g., book, cup, blanket, journal) designed to promote well-being.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Project SOAR Awakenings arm — Four Project SOAR Awakenings sessions will be conducted electronically (Zoom) by experts in a group format (12-18 participants/group) with Black American women diagnosed with breast cancer. The Strong Black Woman concept and other culturally curated topics will be discussed as they apply to group members' experience of breast cancer. All women in the study will receive a care box with resources for Black American women diagnosed with breast cancer.
  • Behavioral: Project SOAR comparison group — Black American women diagnosed with breast cancer in this arm will receive a care box with resources for Black American women diagnosed with breast cancer.

Primary Outcomes

  • Depressive symptoms - Center for Epidemiologic Studies-Depression scale (Baseline, 1 month post-baseline, 4 months post-baseline)
  • Fatigue - PROMIS Fatigue Short Form 7a; range = 7 - 35; higher scores indicate higher fatigue (Baseline, 1 month post-baseline, 4 months post-baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-25
Completion: 2026-07
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, Los Angeles
Collaborators: Breast Cancer Research Foundation
Principal Investigators:
  • Annette L Stanton, PhD (PRINCIPAL_INVESTIGATOR) - University of California, Los Angeles
  • Tammie Denyse, MDiv Dr(Hon) (PRINCIPAL_INVESTIGATOR) - Carrie's TOUCH
Contact Information
Study Contact:
Alexandra Jorge, MA
323-425-9379
projectsoar2018@gmail.com
Annette Stanton, PhD
310-825-3105
astanton@ucla.edu
Annette L Stanton, PhD
310-825-3105
astanton@ucla.edu
UCLA
Interventions
  • Behavioral: Project SOAR Awakenings arm — Four Project SOAR Awakenings sessions will be conducted electronically (Zoom) by experts in a group format (12-18 participants/group) with Black American women diagnosed with breast cancer. The Strong Black Woman concept and other culturally curated topics will be discussed as they apply to group members' experience of breast cancer. All women in the study will receive a care box with resources for Black American women diagnosed with breast cancer.
  • Behavioral: Project SOAR comparison group — Black American women diagnosed with breast cancer in this arm will receive a care box with resources for Black American women diagnosed with breast cancer.
Study Locations (1 sites)
UCLA, Los Angeles, California 90095-1563 United States
Eligibility Criteria
Inclusion Criteria: * identifying as a woman at least 18 years of age (not limited to cisgender Black American women); * identifying as Black (African) American; * diagnosed with breast cancer of any stage and any diagnosis duration; * able to speak and read English; * residing in the United States; * access to the internet/Zoom. Exclusion Criteria: * men diagnosed with breast cancer, * non-English speaker * nonresident of the United States * no internet access

Developing Breast (Cancer) Organoids

NCT05317221
Recruiting
Conditions Breast Cancer
Phase Not Applicable
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

Currently, only a few validated biomarkers and models exist guiding or predicting treatment response for specific patient groups. Therefore, a patient-tailored clinical model needs to be developed to address tumour heterogeneity and thereby guide treatment selection on an individualized level. Organoids are patient-derived aggregates that grow in 3D and maintain self- renewal pluripotency and lineage-specific differentiation. Therefore, in contrast with conventional cell lines, they are thought to sustain patient heterogeneity and characteristics and are consequently already in use for drug response screening. This now offers the opportunity to investigate if the primary patient breast cancer organoid platform reflects disease progression, treatment response and relapse in patients with different clinical breast cancer subtypes. Goal: To develop a living biobank from prospective patient-derived breast cancer tissue. The questions we will address are: 1. Do patient-derived breast cancer organoids retain the clinical behaviour and characteristics of the primary patient tumour? 2. Can BC organoids be used to derive prognostic and predictive biomarkers to inform treatment decisions? 3. Can the investigators utilize BC organoids to discover novel actionable targets and combination treatments for therapeutic intervention for breast cancer patients? 4. Can BC organoids be used to discover mechanisms of treatment resistance and relapse?

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Not an extra intervention, tissue taken in routine practice will be used. — No extra intervention: using tumour tissue taken during surgery in standard of care.

Primary Outcomes

  • Living biobank (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-09-01
Completion: 2028-05-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Maastricht Radiation Oncology
Collaborators: Maastricht University Medical Center, Maastricht University
Principal Investigators:
  • Marc Vooijs, PhD (PRINCIPAL_INVESTIGATOR) - Maastricht University
  • Marjolein Smidt, MD, PhD (PRINCIPAL_INVESTIGATOR) - Maastricht University Medical Center
  • Loes Kooreman, MD (PRINCIPAL_INVESTIGATOR) - Maastricht University Hospital (MUMC+)
Contact Information
Study Contact:
Chantal Overhof
+31 88 44 55 683
chantal.overhof@maastro.nl
Ann Claessens
+31 88 44 55 600
ann.claessens@maastro.nl
Interventions
  • Other: Not an extra intervention, tissue taken in routine practice will be used. — No extra intervention: using tumour tissue taken during surgery in standard of care.
Study Locations (1 sites)
Maastricht University Medical Center, Maastricht, 6202 AZ Netherlands
Eligibility Criteria
Inclusion Criteria: * Female, * \>18 years, * Family Anamneses * Breast cancer (proven by histopathology), Included subtypes; (ER-,PR- HER2-); (ER+, PR+, HER2-); (ER+, PR+ HER2+). * Primary surgery (lumpectomy or mastectomy) Exclusion Criteria: \- Physically or mentally incapable or incompetent to sign informed consent

National Mammography Database

NCT01900821
Recruiting
Conditions Breast Cancer Screening and Diagnosis
Phase Not Applicable
Enrollment 8000000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

The National Mammography Database (NMD) leverages data that radiology practices are already collecting under federal mandate by providing them with comparative information for national and regional benchmarking. Participants receive semi-annual feedback reports that include important benchmark data such as cancer detection rates, positive predictive value rates and recall rates. Participation in the NMD is free to Breast Imaging Center of Excellence (BICOE) facilities.

Design

Study type: Observational Observational model: Ecologic Or Community Time perspective: Prospective

Primary Outcomes

  • Cancer Detection Rate (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2009-07
Completion: 2026-12
Eligibility
Age: 2 Years and older
Sex: ALL
Volunteers: true
Enrollment: 8000000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: American College of Radiology
Contact Information
Study Contact:
Mythreyi B Chatfield, PhD
703-715-4394
mchatfield@acr.org
Interventions
N/A
Study Locations (1 sites)
ACR, Reston, Virginia 20190 United States
Eligibility Criteria
Inclusion Criteria: * All Exclusion Criteria: * None
Conditions Psoriasis (PsO), Obesity & Overweight, D...
Phase PHASE4
Enrollment 62
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate the effects of oral semaglutide in combination with topical corticosteroid/calcipotriol on clinical outcomes and metabolic inflammation in patients with plaque psoriasis and overweight/obesity and/or type 2 diabetes mellitus. A total of 62 participants will be randomized to receive either semaglutide plus topical corticosteroid/calcipotriol or placebo plus topical corticosteroid/calcipotriol for 12 weeks. Clinical efficacy will be assessed using the Psoriasis Area and Severity Index (PASI), and quality of life will be evaluated using DLQI, PROMIS-29, and EQ-5D-5L. Systemic inflammatory markers will also be measured to assess metabolic inflammation.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Semaglutide (Rybelsus®) — Oral semaglutide will be administered once daily at a dose of 3 mg for the first 4 weeks, followed by 7 mg once daily for the next 4 weeks, and 14 mg once daily for the final 4 weeks (total treatment duration: 12 weeks). All participants will also receive conventional topical therapy for 12 weeks, consisting of a topical corticosteroid and a vitamin D analog (calcipotriol).
  • Drug: Placebo — A total of 31 participants will be randomly assigned to the placebo intervention group. They will receive a daily placebo tablet containing starch for 12 weeks. All participants will also receive conventional topical therapy for 12 weeks, consisting of a topical corticosteroid and a vitamin D analog (calcipotriol).

Primary Outcomes

  • Effect of GLP-1 Receptor Agonists on SCD-1 Activity (Baseline to Week 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-01-15
Completion: 2027-02-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 62 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospital Universitario Dr. Jose E. Gonzalez
Contact Information
Study Contact:
Jorge Valdespino, MD
+52 8771093680
jorge.valdespino@outlook.com
Jorge Valdespino Valdes, MD
+52 8771093680
jorge.valdespino@outlook.com
Hospital Universitario Dr. José E. González
Interventions
  • Drug: Semaglutide (Rybelsus®) — Oral semaglutide will be administered once daily at a dose of 3 mg for the first 4 weeks, followed by 7 mg once daily for the next 4 weeks, and 14 mg once daily for the final 4 weeks (total treatment duration: 12 weeks). All participants will also receive conventional topical therapy for 12 weeks, consisting of a topical corticosteroid and a vitamin D analog (calcipotriol).
  • Drug: Placebo — A total of 31 participants will be randomly assigned to the placebo intervention group. They will receive a daily placebo tablet containing starch for 12 weeks. All participants will also receive conventional topical therapy for 12 weeks, consisting of a topical corticosteroid and a vitamin D analog (calcipotriol).
Study Locations (1 sites)
Hospital Universitario Dr. José E. González, Monterrey, N.L. 64460 Mexico
Eligibility Criteria
Inclusion Criteria: * Male or female participants aged ≥18 years at the time of randomization. * Clinical diagnosis of plaque psoriasis with Psoriasis Area and Severity Index (PASI) ≥3 and body surface area (BSA) ≥3%. * Body mass index (BMI) ≥25 kg/m², consistent with overweight or obesity. * Participants with or without type 2 diabetes mellitus. * Participants with diabetes must be on stable antidiabetic therapy (no changes in medication or dosage within the previous 3 months) and have adequate glycemic control, defined as HbA1c ≤9.0% at baseline. * No use of systemic psoriasis therapies (e.g., methotrexate, cyclosporine) for at least 8 weeks prior to randomization. * No use of biologic therapies for at least 3 months prior to randomization. Exclusion Criteria: * Diagnosis of a non-plaque psoriasis subtype, including pustular, guttate, nail, inverse, psoriatic arthritis, or erythrodermic psoriasis. * Pregnancy or breastfeeding at the time of screening or enrollment. * Insulin-dependent diabetes mellitus or current use of sulfonylureas. * Active malignancy at the time of screening. * History of thyroid neoplasia. * Presence of autoimmune diseases. * Use of systemic therapies within 8 weeks prior to randomization. * Use of biologic therapies within 3 months prior to randomization. * Renal insufficiency. * Heart failure. * Hepatic insufficiency. * History of pancreatitis. * Current treatment with other GLP-1 receptor agonists. * History of inflammatory bowel disease. * Known allergy to starch.
Conditions Diabetes, Diabetic Retinopathy, Type 2 D...
Phase Not Applicable
Enrollment 2920
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to integrate clinical indicators and features of fundus images, combined with metabolomics, to construct an early warning model for diabetic retinopathy (DR) in type 2 diabetes. By combining clinical indicators with metabolomics, the investigators aim to establish a precise DR typing model based on the age of diabetes onset (early-onset diabetes, late-onset diabetes) and based on the coexistence with two types of diabetic macrovascular complications. A multidisciplinary collaboration will be conducted for comprehensive management of DR to control the progression of moderate-stage DR. Cloud-based patient rooms combined with continuous glucose monitoring (CGM) will further explore the role of integrated diabetes retinopathy ward management models in the management of patients undergoing diabetes retinopathy surgery, pioneering a new model for the management of advanced DR.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Fundus Examination — Performing fundus photography on patients to assess the progression of diabetic retinopathy (DR).
  • Diagnostic Test: Metabolomics analysis — Conduct metabolomics testing at enrollment.

Primary Outcomes

  • Fundus examination (Conduct examinations at enrollment and twelve months after enrollment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-02-01
Completion: 2028-07-31
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 2920 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yufan Wang
Contact Information
Study Contact:
Liping Gu Liping Gu
86-13564720656
guliping1980@126.com
Jie Han Jie Han
13893633986
540441755@qq.com
The first hosptial of lanzhou university
Liping Gu Liping Gu
13564720656
guliping1980@126.com
Shanghai general hosptial
Interventions
  • Diagnostic Test: Fundus Examination — Performing fundus photography on patients to assess the progression of diabetic retinopathy (DR).
  • Diagnostic Test: Metabolomics analysis — Conduct metabolomics testing at enrollment.
Study Locations (3 sites)
The first hosptial of lanzhou university, Lanzhou, China
Shanghai general hosptial, Shanghai, China
The forth people's hosptial of shenyang, Shenyang, China
Eligibility Criteria
Inclusion Criteria: * Meets the diagnostic criteria for type 2 diabetes in the "China Type 2 Diabetes Prevention and Treatment Guidelines (2020 Edition)"; * Aged between 20 and 79 years old, without other severe underlying diseases; ③ Possesses full cognitive and literacy abilities; ④ Volunteers to participate in this study and are willing to sign an informed consent form. Exclusion Criteria: * Those who have been diagnosed with type 1 or other types of diabetes; * Those with severe cardiac, pulmonary, hepatic, or renal insufficiency; * Those with mental confusion, speech disorders, or dementia, etc.; * Those who are unable to take care of themselves, bedridden, or have mobility impairments; ⑤ Women who are breastfeeding or pregnant; * Those with a recent history of surgery, trauma, acute major vascular complications, or infectious diseases.
Conditions Type2diabetes, Diabetic Kidney Disease
Phase PHASE2
Enrollment 156
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

A phase 2a trial randomized, double-blind, placebo-controlled, parallel group trial to determine whether NMN administration improves DKD, as indicated by a significantly greater reduction in UACR compared with placebo administration. Eligible participants will be randomized to receive either 1000 mg NMN or placebo twice daily.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Investigational Product - MIB 626 — The eligible participants will be assigned to receive either NMN or placebo using concealed block randomization in a 1:1 ratio, stratified by sex (male, female), age (60 to 75, \>75 years) and trial site. The randomization list will be generated by the unblinded biostatistician using the software R (www.r-project.org), and deployed in a secure, centralized web-based application accessible to study staff following confirmation of a participant's eligibility.
  • Drug: Placebo — Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC.

Primary Outcomes

  • The primary endpoint is the change from baseline in UACR over the 6-month intervention period. (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-04-13
Completion: 2027-03-31
Eligibility
Age: 30 Years and older
Sex: ALL
Volunteers: false
Enrollment: 156 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Brigham and Women's Hospital
Collaborators: Boston Medical Center
Principal Investigators:
  • Shalender Bhasin, MD (PRINCIPAL_INVESTIGATOR) - Brigham and Women's Hospital
Contact Information
Study Contact:
Shalender Bhasin, MD
6175259150
sbhasin@bwh.harvard.edu
Nancy Latham, PhD
6179999195
nklatham@bwh.harvard.edu
Nancy K Latham, PhD
6179999195
nklatham@bwh.harvard.edu
Brigham and Women's Hospital
Interventions
  • Drug: Investigational Product - MIB 626 — The eligible participants will be assigned to receive either NMN or placebo using concealed block randomization in a 1:1 ratio, stratified by sex (male, female), age (60 to 75, \>75 years) and trial site. The randomization list will be generated by the unblinded biostatistician using the software R (www.r-project.org), and deployed in a secure, centralized web-based application accessible to study staff following confirmation of a participant's eligibility.
  • Drug: Placebo — Placebo - Participants randomized to placebo will receive Matching placebo tablets will be provided by Metro International Biotech, LLC.
Study Locations (1 sites)
Brigham and Women's Hospital, Boston, Massachusetts 02115 United States
Eligibility Criteria
Inclusion Criteria: 1. A man or a postmenopausal woman (complete cessation of menses for one or more years and /or FSH \> 20 U/L), 30 years or older 2. Has type 1 or type 2 diabetes mellitus, as indicated by any of the following: 1. Self-report of type 1 or type 2 diabetes plus the use of a prescribed medication. 2. ICD-10 code for type 1 or type 2 diabetes plus current use of a medication in the electronic medical record. 3. HbA1c \>6.4%; or 2 fasting glucose \> 125 mg/dL 3. Has an average of two or more morning UACR equal to or above 100mg/g creatinine each of which must be equal to or greater than 60 mg / g creatinine with at least one UACR value measured during the screening visit. a. Recent UACR value in the medical record within the preceding 3 months prior to screening is acceptable. 4. If type 2 diabetic and UACR is \> 300 mg/g creatinine, must be currently using an ACE inhibitor or an ARB or a SGLT2 inhibitor. 5. eGFR \> 25 mL/ min / 1.73 m2 6. Hemoglobin A1c \<10% 7. Able to speak English or Spanish or Haitian Creole 8. Willing and able to provide written informed consent 9. In addition, female participants must Not be pregnant and not planning to become pregnant over the next 6 months. Exclusion criteria: 1. Fasting morning UACR \> 5,000 mg/ g creatinine 2. Other laboratory abnormalities: 1. Has AST or ALT \> 3 times the upper limit of normal 2. eGFR \< 25 mL/ min / 1.73 m2 3. Hematocrit \< 0.34 or \> 0.50 L/L 3. A major adverse cardiovascular event in preceding 3 months 4. Participation in an investigational trial to evaluate pharmaceuticals or biologics within the past 3 months or 5 half-lives, whichever is shorter 5. Current alcohol or substance use disorder or dependence (DSM 5 criteria). 6. Major depressive disorder, bipolar disorder, schizophrenia, or current psychotic symptoms or behavioral problems that could interfere with study procedures. 7. An acute illness, including COVID-19, requiring hospitalization within the past 3 months or any acute illness, including COVID-19, within the past month. 8. Has a history of anaphylaxis from vitamin B3 derivatives 9. BMI \> 42.5 kg/ m2 10. If patient has a confirmed diagnosis of type 3 diabetes, or gestational diabetes.
Conditions Diabetes in Pregnancy, Type 2 Diabetes
Phase NA
Enrollment 56
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to compare the use of hydroxychloroquine as an adjunct to the current treatment of pregnant women with Type 2 diabetes mellitus. The main questions it aims to answer are: * Does hydroxychloroquine improve the pregnancy outcomes in women with type 2 diabetes during pregnancy? * Does hydroxychloroquine improve the inflammatory markers in women with type 2 diabetes during pregnancy? Participants will be randomised into the intervention and control group. The control group will be on standard treatment where as the intervention group will receive hydroxychloroquine as an adjunct of standard treatment

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Hydroxychloroquine Oral Tablet — 200mg daily

Primary Outcomes

  • To compare the serum glycated haemoglobin (HbA1c) between the two groups (From Day 1 up to 38 weeks of gestation)
  • To compare the serum fructosamine between the two groups (From Day 1 up to 38 weeks of gestation)
  • To compare the serum interleukin-6 between the two groups (From Day 1 up to 38 weeks of gestation)
  • To compare the serum interleukin-10 between the two groups (From Day 1 up to 38 weeks of gestation)
  • To compare the serum tumour necrosis factor alpha between the two groups (From Day 1 up to 38 weeks of gestation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-24
Completion: 2027-01-01
Eligibility
Age: 20 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 56 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National University of Malaysia
Principal Investigators:
  • Rahana Abd Rahman (PRINCIPAL_INVESTIGATOR) - UKM
Contact Information
Study Contact:
Rahana Abdul Rahman, MD
039145
drrahana@ukm.edu.my
Rahana Abd Rahman
Antenatal clinic, UKM Medical Centre
Interventions
  • Drug: Hydroxychloroquine Oral Tablet — 200mg daily
Study Locations (1 sites)
Antenatal clinic, UKM Medical Centre, Cheras, Kuala Lumpur 56000 Malaysia
Eligibility Criteria
Inclusion Criteria: * Singleton * Pregnant women with a confirmed diagnosis of type 2 Diabetes Mellitus Exclusion Criteria: * autoimmune disease such as Systemic Lupus Erythematosus or rheumatic disease * chronic kidney disease * fetal anomaly * women on steroid therapy * diabetic retinopathy * known thalassaemia or thalassaemia carrier
Conditions Irritable Bowel Syndrome, Crohn Disease,...
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

The SIMBA Capsule is a small, single-use, ingestible capsule that allows for the non-invasive sampling of small bowel contents using purely mechanical means. The study will compare the microbial and metabolomics analysis from the sample collected with the capsule series, to same-participant symptom questionnaires and stool microbial analysis.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Interventions / Regimen

  • Device: fluid biopsy capsule — Collection of a fluid biopsy from the small intestine via ingestible capsule

Primary Outcomes

  • Correlation of bacterial composition with gastrointestinal disease states as assessed by PLS-DA mapping. (baseline, pre-procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-01-09
Completion: 2025-06-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nimble Science Ltd.
Collaborators: Mitacs, University of Calgary
Principal Investigators:
  • Chris Andrews, MD (PRINCIPAL_INVESTIGATOR) - Nimble Science Ltd.
  • Matthew Woo, MD (PRINCIPAL_INVESTIGATOR) - Nimble Science Ltd.
Contact Information
Study Contact:
Gwen Duytschaever, PhD
8664934633
clinical@nimblesci.com
Gwen Duytschaever, PhD
8664934633
clinical@nimblesci.com
Nimble Science
Chris Andrews, MD
Nimble Science
Interventions
  • Device: fluid biopsy capsule — Collection of a fluid biopsy from the small intestine via ingestible capsule
Study Locations (1 sites)
Nimble Science, Calgary, Alberta T2P 3P2 Canada
Eligibility Criteria
Inclusion Criteria: 1. 1\. Aged between 18 and 80 years. 2. No previous diagnosis of Celiac Disease, Ulcerative Colitis, Crohn's disease, IBS, Functional Dyspepsia, and T2D by participant self-report (Control group). 3. Prior diagnosis of Celiac Disease, Ulcerative Colitis, Crohn's disease, IBS, or Functional Dyspepsia, and T2D by a relevant physician, nutritionist, naturopath, etc, and willingness to provide documentation to confirm this diagnosis or have a consultation with the PI. (Disease group). 4. Ability to understand and provide informed consent. 5. Ability and willingness to meet the required schedule, study interventions, and questionnaire requirements. 6. No planned change in diet or medical interventions during the study duration. Exclusion Criteria 1. Known disease which, in the investigator's opinion, would lead to intestinal structuring or obstruction with a risk of capsule non-excretion (particular diseases which would be assessed on a case-by-case basis would include, achalasia, eosinophilic esophagitis, cancer diagnosis or treatment within the past year, or previous esophageal, gastric, small intestinal, or colonic surgery. Appendectomy or cholecystectomy more than 3 months prior to enrollment are acceptable). The main deciding factor would be a history of obstructive symptoms in the previous 3 months prior to entry. 2. Use of any medications or having undergone procedures in the previous week that could substantially alter gastrointestinal motor function (e.g., opioids, anticholinergics, laxatives, or GLP-1 analogues). 1. Stimulant laxative use (includes bisacodyl/Dulcolax, senna/Senekot, cascara, or fibre supplments) is allowed if it is kept unchanged in the week prior to the SIMBA Capsule ingestion. Osmotic laxatives (polyethylene glycol (PEG; other trade names), milk of magnesia, lactulose), stool softeners (docusate; other trade names) or secretagogues (linaclotide/Constella, plecanatide/Trulance, tenapanor/Ibsrela should not be used within 7 days of taking the SIMBA capsules. 2. Prokinetics use is allowed if kept unchanged in the week prior to the SIMBA Capsule ingestion (includes domperidone, metoclopramide, prucalopride). Inconsistent use of prokinetics will be evaluated by the PI. 3. PPI or H2RA use. Must be able to discontinue PPI or H2RA medications 48hrs prior to SIMBA capsule ingestion, medication can be resumed 4 hours after ingestion. 3. History of oropharyngeal dysphagia or other swallowing disorder with a risk of aspiration of the capsule. 4. History of known structural gastrointestinal abnormalities such as strictures or fistulas leading to mechanical obstruction 5. History of abdominal radiation treatment 6. Females of childbearing age who are pregnant or lactating by self-report. (should an X-ray be required for confirmation of capsule passage, a urine pregnancy test will be administered beforehand). 7. No antibiotics, or colon cleanses/bowel prep for 2 weeks. 8. \< 2 bowel movements per week (Control Group only).
Conditions Obesity, Type 2 Diabetes
Phase Not Applicable
Enrollment 930
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-28
Study Details Design, interventions, and primary outcomes

About This Study

Background: Type 2 diabetes is a disease that affects blood sugar levels. Complications can include heart and blood vessel (vascular) diseases. Rates of type 2 diabetes have tripled in children and young adults over the last 40 years. Vascular diseases are also increasing in young people. Objective: To learn more about factors, including type 2 diabetes, that may cause vascular disease in young people. Eligibility: People aged 12 to 25 years who (1) have type 2 diabetes; (2) are overweight but not diabetic; (3) or are lean and healthy. Biological parents are also needed. Design: Young participants will visit the NIH clinic once a year for up to 25 years. Each visit will take 4 days. Before each visit, participants will wear devices to track their sleep, activity, and blood sugar levels for 7 to 10 days. At each visit, participants will have tests including: Samples: They will provide blood, urine, and stool samples. Heart: They will ride a stationary bike for 6 minutes with stickers applied to their chest. Scans: They will lie on a bed that slides into a tube; the machine will take pictures of the inside of their body. Energy: They will wear a hood over their head to measure the air they breathe. Social stress: They will give a speech for 10 minutes to show their body s response to stress. Glucose: They will drink a sweet drink to see how their blood sugar changes. Biological parents will have 1 study visit. They will have blood tests. They will fill in questionnaires about their lifestyle and stress. ...

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Pulse wave velocity (PWV) (Baseline)
  • Augmentation index (Aix) (Baseline)
  • Pulse wave velocity (PWV) (5 Years)
  • Augmentation index (Aix) (5 Years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-12
Completion: 2033-10-31
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: true
Enrollment: 930 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigators:
  • Stephanie T Chung, M.D. (PRINCIPAL_INVESTIGATOR) - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Contact Information
Study Contact:
Lilian S Mabundo
(240) 383-9379
lilian.mabundo@nih.gov
Stephanie T Chung, M.D.
(240) 479-8137
stephanie.chung@nih.gov
Doris Estrada
202-476-2121
destrada@childrensnational.org
Children's National Hospital (CNH)
Interventions
N/A
Study Locations (2 sites)
Children's National Hospital (CNH), Washington D.C., District of Columbia 20010 United States
National Institutes of Health Clinical Center, Bethesda, Maryland 20892 United States
Eligibility Criteria
* INCLUSION CRITERIA: To be eligible to participate in this study, an individual must meet the following criteria according to their group: Four categories of participants will be included in this study and the inclusion criteria for each group are given below: 1. Participants with Y-T2DM 1a.Age 12-25 years 1b.Type 2 diabetes mellitus as defined by fasting blood glucose \>= 126 mg/dL OR postprandial blood sugar \>= 200 mg/dL OR Hemoglobin A1c \>= 6.5% per American Diabetes Association Criteria and one element from the medical history consistent with ADA or AAP guidelines including: family history of diabetes and obesity, maternal or personal history of gestational diabetes, high-risk race and ethnicity, history of cardiovascular disease, hypertension, dyslipidemia, polycystic ovary syndrome, physical inactivity, other clinical conditions associated with insulin resistance (e.g. severe obesity, acanthosis nigricans, prediabetes), small or large for gestational age birth weight, history of breastfeeding, gestational history of illicit drugs including alcohol, smoking OR documentation of type 2 diabetes diagnosed at \<=25 years of age with verified medical history (as above). 2\. Youth with overweight/ obesity (Y-OW) 2a. Age 12-25 years 2b. For participants \< 18 years of age, BMI \>= 85th percentile (overweight) and \>= 95th percentile (obesity) for age and sex OR 2c. For participants \>= 18 years of age, BMI \>=25\<30 kg/m\^2 (overweight) or \>=30 kg/m\^2 (obesity) 2d. Participants with obesity may have a diagnosis of prediabetes, defined as fasting blood glucose 100-125 mg/dL OR postprandial blood sugar 140-199 mg/dL OR HbA1c 5.7-6.4 percent (either during testing at NIH or as previously documented on outside medical record). 3\. Healthy control lean participants (Y-Lean) 3a. Age 12-25 years 3b. For participants \< 18 years of age, BMI \<= 85th percentile for age and sex OR 3c. For participants \>=18 years of age, BMI 18-24.99 kg/m\^2. 3d. HbA1c \<5.7 percent (either during testing at NIH or as previously documented on outside medical record). 4\. Biological parents of Y-T2DM, Y-OW and Y-Lean participants 4a. Biological parent of enrolled Y-T2DM, Y-OW and Y-Lean by self-report. EXCLUSION CRITERIA: An individual who meets any of the following criteria for their specific group will be excluded from participation in this study: 1\. Y-T2DM, Y-OW and Y-Lean Participants: 1a. Type 1 diabetes or the presence of \>2 diabetes auto-antibodies (e.g., GAD-65, IA-2 antigen, Zinc transporter 8 autoantibodies). 1. b. Medical, psychiatric or cognitive disorders that will, in the opinion of the investigators, limit the subject s ability to comply with study procedures (specific obesity-related comorbidities are explicitly permitted, including hypertension, hyperlipidemia, obstructive sleep apnea and non-alcoholic steatohepatitis). 1c. Serious medical illnesses or diseases thought to alter metabolism (including moderate to severe renal disease (\< 30 mL/min/1.73m\^2), congenital heart disease, Cushing s syndrome, cancer, or other metabolic diseases associated with diabetes or excess weight). 1d. For participants enrolled at the NIH, dietary allergies, intolerances or eating patterns that would preclude them from consuming metabolic meals. 1e. Unwilling to comply with all study procedures or to adhere to Lifestyle Considerations throughout study duration. 1f. Pregnancy at the time of the screening visit. 1g. Clinically significant anemia OR Hematocrit below the lower limit of normal for age and sex cutoffs. 1. h. For Y-OW Participants- Meet lab and medical history criteria for Y-T2DM as described in inclusion criterion 1b above. 2\. Y-Lean participants: In addition to the above exclusion criteria, any Y-Lean participant who meets any of the following additional criteria will be excluded from the study: 2a. Current use of prescription or non-prescription medication. Certain exceptions are permitted, including topical medications, vitamins, and hormonal contraceptives. Other medications may be permitted at the discretion of the investigators. 2b. Recent (past 2 months) use of drugs or supplements that alter glucose or lipid metabolism (e.g., niacin, fish oil, red yeast rice) 2c. History of diabetes or abnormal glucose tolerance 2d.. Abnormal screening labs, including the following: i) ALT or AST \>2 times the upper limit of normal ii) Glycosuria iii) Low eGFR (\<90 mL/min/1.73m\^2)Any other abnormality that, in the opinion of the investigator, will increase risk to the subject from participation, or interfere with interpretation of study data 2e. Meet lab and medical history criteria for Y-T2DM as described in inclusion criterion 1b above. 3\. Biological Parents -No Exclusion Criteria